NIH Dental Institute Schedules Virtual Grant Review Meeting
Published Date: 12/18/2025
Notice
Summary
The National Institute of Dental & Craniofacial Research is holding a virtual meeting on January 21, 2026, to share updates and review grant applications. This meeting affects researchers and organizations seeking funding for dental and craniofacial studies. The open session is free to watch online, while the closed session will protect private info and trade secrets.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Open Session Videocast Is Free
You can watch the National Advisory Dental and Craniofacial Research Council open session live by videocast on January 21, 2026 from 11:15 a.m. to 2:15 p.m. Registration is not required and the videocast is available from the NIH Videocasting website. If you need sign language interpretation or other reasonable accommodations, you should notify the listed Contact Person or use the Federal Relay at 1-800-877-8339 in advance.
Confidential Grant Review Protections
The meeting includes a closed session on January 21, 2026 from 2:45 p.m. to 4:30 p.m. to review and evaluate grant applications where discussions may disclose confidential trade secrets, patentable material, or personal information; those matters are closed under 5 U.S.C. 552b(c)(4) and (c)(6). This protects researchers and organizations seeking funding by keeping proprietary and private application information out of the public record.
How to Submit Written Comments
Any interested person may file written comments with the committee by sending a statement to the listed Contact Person; the statement should include your name, address, telephone number, and, if applicable, your business or professional affiliation. Information and meeting agendas will also be posted on the Institute's advisory council webpage.
Backup Grant Review Date Scheduled
If the Council cannot complete all agenda items on January 21, 2026, a backup virtual meeting is scheduled for March 17, 2026 with a closed session from 2:00 p.m. to 3:30 p.m. to review any remaining grant applications. Researchers and organizations seeking funding should note this alternate date for possible evaluation of their applications.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-23207, Determination Pursuant to Section 102 of the Illegal Immigration Reform and Immigrant Responsibility Act of 1996, as Amended
Starting December 18, 2025, the Department of Homeland Security is speeding up the building of barriers and roads along the New Mexico border by temporarily skipping some usual rules. This move helps stop illegal crossings and keeps the country safer. It affects border construction projects and shows the government’s serious commitment to border security without delay.
Next: 2025-23209, Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority
The FCC is checking in on its paperwork for geo-targeted emergency alerts to make sure it’s useful and not too much work. They want your thoughts by February 17, 2026, especially from small businesses and local governments who use these alerts. This review won’t cost you much time—just about 7 minutes per response—and helps keep emergency alerts sharp and effective.